<< Back to News

System Formulary Update
Phosphodiesterase-5 Enzyme Inhibitors

Situation

The phosphodiesterase-5 enzyme inhibitors class review and formulary standardization was approved at the November 2020 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: avanafil, sildenafil, tadalafil, vardenafil

Assessment/Recommendation

Changes effective: Tuesday January 12, 2021

System P&T voted to include the following products on the UNC Health Medication Formulary:

• Restricted to patients with pulmonary hypertension
  • Sildenafil tablet
  • Sildenafil oral suspension
  • Tadalafil tablet
• Restricted to the following (must meet all criteria): NICU/NCCC and PICU use and patients with pediatric pulmonary hypertension or congenital diaphragmatic hernia
  • Sildenafil injection

Note: Stock of these formulary products may vary at individual entities

As a result, the following products will be removed from the UNC Health Medication Formulary:

• Avanafil
• Vardenafil